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Simian virus 40 (SV40) is a nonenveloped virus that has been shown to pass from surface caveolae
to the endoplasmic reticulum in an apparently novel infectious entry pathway. We now show that
the initial entry step is blocked by brefeldin A and by incubation at 20°C. Subsequent to the entry
step, the virus reaches a domain of the rough endoplasmic reticulum by an unknown pathway.
This intracellular trafficking pathway is also brefeldin A sensitive. Infection is strongly inhibited
by expression of GTP-restricted ADP-ribosylation factor 1 (Arf1) and Sar1 mutants and by
microinjection of antibodies to COP. In addition, we demonstrate a potent inhibition of SV40
infection by the dipeptide N-benzoyl-oxycarbonyl-Gly-Phe-amide, which also inhibits late events
in cholera toxin action. Our results identify novel inhibitors of SV40 infection and show that SV40
requires COPI- and COPII-dependent transport steps for successful infection.
INTRODUCTION
Viruses have exploited endocytic pathways to overcome the
barrier presented by the plasma membrane and enter animal
cells. Although the entry of viruses via clathrin-coated pits
has been extensively studied and is well understood (Marsh
et al., 1984), entry of viruses by alternative pathways has
been less well characterized. Simian virus 40 (SV40) is a
nonenveloped virus that uses an apparently unique entry
route to reach the nucleus of animal cells. SV40 binds to
major histocompatibility complex (MHC) class I molecules
on the cell surface (Breau et al., 1992) and then is observed in
tight-fitting, nonclathrin-coated pits (Kartenbeck et al., 1989;
Anderson et al., 1996; Stang et al., 1997; Norkin, 1999; Parton
and Lindsay, 1999). These pits are enriched in caveolin-1 but
are smaller than caveolae, raising the possibility that caveo-
lin is recruited around the virus (Stang et al., 1997). Consis-
tent with this model, the levels of caveolin-1 associated with
virus-containing membranes were shown to increase with
time (Stang et al., 1997). Subsequently, the virus is internal-
ized in a process that is sensitive to cholesterol-perturbing
agents (Anderson et al., 1996). The role of caveolin in this
process is suggested by the finding that viral infection is also
inhibited by dominant negative mutants of caveolin (Roy et
al., 1999). Viral entry apparently occurs without concomitant
internalization of MHC class I (Anderson et al., 1998), in a
process dependent on tyrosine kinase activity (Dangoria et
al., 1996; Chen and Norkin, 1999; Norkin, 1999). Early elec-
tron microscopic studies suggested that the virus is then
transported directly to the endoplasmic reticulum (ER) be-
cause no intermediate stations were identified (Kartenbeck
et al., 1989). A direct pathway between the cell surface and
ER would be a novel finding, although parallels can be made
to the cholesterol oxidase-induced redistribution of caveo-
lin-1 from caveolae to the lumen of the ER (Smart et al.,
1994).
The virus eventually reaches the nucleus where uncoating
and replication occur. At some stage in the entry pathway
the SV40 virions appear to translocate across a membrane
into the cytosol and then enter the nucleus via the nuclear
pore complexes (Clever et al., 1991; Yamada and Kasamatsu,
1993). Cytosolic microinjection of antibodies against viral
proteins blocks the infection process (Nakanishi et al., 1996),
suggesting that the virus is actually free in the cytosol at
some stage in infection but the mechanism by which trans-
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location into the cytosol occurs, and the compartment in-
volved in this process, are unknown.
Many toxins are retrogradely transported from the cell
surface to the ER where translocation into the cytosol occurs.
This has provided important insights into the retrograde
transport process and the mechanisms involved in translo-
cation. This process has been particularly well characterized
for cholera toxin (CT). CT binds via its binding subunits to
the ganglioside GM1 at the cell surface. GM1 is slightly
enriched in caveolae but is present over the entire cell sur-
face, including clathrin-coated pits (Parton, 1994). Inhibitor
studies, using cholesterol-disrupting agents, have suggested
that CT is internalized via caveolae (Orlandi and Fishman,
1998). However, CT is also efficiently internalized, in a cho-
lesterol-dependent process, in cells lacking caveolae (Or-
landi and Fishman, 1998). Elegant studies using chimeric
toxins have shown that association with raft domains is
critically important for toxic entry of CT (Wolf et al., 1998).
Internalization of CT and budding of caveolae have both
been proposed to be dynamin dependent (Henley et al.,
1998; Orlandi and Fishman, 1998). After internalization CT
passes to endosomes and then the trans-Golgi network. The
toxin then arrives at the ER in a process that can be blocked
experimentally by brefeldin A (BFA) and by microinjection
of coatomer antibodies (Lencer et al., 1993; Nambiar et al.,
1993; Majoul et al., 1998; Girod et al., 1999). This process is
facilitated by a KDEL sequence in the A subunit and re-
trieval by the KDEL receptor (Majoul et al., 1998). On reach-
ing the ER, redox-dependent unfolding of the toxin by pro-
tein disulfide isomerase occurs (Tsai et al., 2001). The A
subunit is then reduced to produce the enzymatically active
A1 peptide, which is translocated to the cytosol via the Sec61
channel, identifying the rough ER as the compartment from
which translocation occurs (Schmitz et al., 2000).
Although recent morphological studies have suggested
the involvement of a novel endosomal intermediate, termed
a caveosome, in the SV40 entry pathway (Pelkmans et al.,
2001), the molecular mechanisms directing SV40 along this
pathway and the similarities to known trafficking pathways
are still unknown. Possible parallels between the SV40 path-
way and that of CT are evident with both suggested to
involve caveolae, the ER, and then translocation to the cy-
tosol (Parton and Lindsay, 1999). This prompted us to ex-
amine SV40 infectious entry by using a range of manipula-
tions previously shown to inhibit CT toxicity. We now show
that SV40 infection is blocked by BFA, with inhibition at two
distinct steps: the initial virus entry step and an intracellular
step. Infection is also blocked by a dominant negative ADP-
ribosylation factor 1 (Arf1) mutant, by a dominant negative
Sar1 mutant, and by microinjection of antibodies to COP.
These results indicate that SV40 infection either proceeds via
a membrane trafficking pathway involving Golgi intermedi-
ates or requires a functional exocytic pathway. We com-
pared the effect of these inhibitors of SV40 infection on CT
entry and show that CT transport from early endosomes to
the Golgi complex is inhibited by both Arf1 and Sar1 mu-
tants. We also show that a novel inhibitor of late events in
CT toxicity, the dipeptide N-benzoyl-oxycarbonyl-Gly-Phe-
amide (Cbz-gly-phe-NH2), blocks late intracellular steps in
SV40 infection, providing new insights into this novel virus
entry pathway.
MATERIALS AND METHODS
Antibodies and Reagents
The expression plasmids encoding Arf1(Q71L) (Pepperkok et al.,
1998; Girod et al., 1999), Sar1(H79G) (Aridor et al., 1995; Pepperkok
et al., 1998), and green fluorescent protein (GFP)-tagged tempera-
ture-sensitive vesicular stomatitis virus glycoprotein (ts-045-G)
(Scales et al., 1997), and affinity-purified anti-COP (EAGE) (Pep-
perkok et al., 1993) have been described previously. Anti-COP
(EAGE) antiserum (used for immunofluorescence labeling) and
mouse monoclonal antibodies to protein disulfide isomerase (PDI)
(Pizarro-Cerda et al., 1998) were kind gifts of Drs. Rohan Teasdale
and Jenny Stow, respectively (Institute for Molecular Bioscience,
Queensland, Australia). Rabbit neutralizing antiserum to SV40 (Bu-
tel et al., 1984) from Dr. Janet Butel (Department of Molecular
Virology and Microbiology, Baylor College of Medicine, Houston,
TX), affinity-purified anti-p23 (Rojo et al., 1997) from Dr. Manuel
Rojo (Department of Biochemistry, University of Geneva, Switzer-
land), human antiserum to EEA1 from Dr. Ban-Hock Toh (Mel-
bourne, Australia), and murine antigiantin (Linstedt and Hauri,
1993) from Dr. Hans-Dieter Soeling (Gottingen, Germany) were also
generous gifts. Murine monoclonals against caveolin-3 (Transduc-
tion Laboratories, Lexington, KY), GM130 (Transduction Laborato-
ries), and SV40 T-antigen (PharMingen, San Diego, CA) were com-
mercially obtained. Brefeldin A, Cbz-gly-phe-NH2, Cbz-gly-gly-
NH2, fluorescein isothiocyanate (FITC)-conjugated CT-B subunit,
unlabeled holotoxin, and antiserum to CT were obtained from Sig-
ma-Aldrich (St. Louis, MO). 4,6-Diamidino-2-phenylindole (DAPI)
and Texas Red-conjugated transferrin were from Molecular Probes
(Eugene, OR). Media and cell culture reagents were purchased from
Invitrogen (Carlsbad, CA) or BioWhittaker (Walkersville, MD).
Cell Culture and Viral Infections
Vero cells (African green monkey kidney cells, ATCC CCL 81) and
CV1 cells (African green monkey kidney cells, ATCC CCL 70) were
maintained in DMEM supplemented with 10% (vol/vol) serum
supreme (BioWhittaker) and 2 mM l-glutamine plus or minus pen-
icillin (100 U/ml) and streptomycin (100 g/ml). Stocks of recom-
binant Semliki Forest virus (SFV) encoding caveolin-3 (from Dr.
Elina Ikonen, National Public Health Institute, Helsinki, Finland)
were diluted into serum-free medium containing 2 mM l-glutamine
and 0.2% bovine serum albumin before addition to cells. After 1 h of
infection at 37°C, cells were washed and infection allowed to pro-
ceed for 5 h or more before fixation and immunolabeling for caveo-
lin-3 to detect successfully infected cells. Preparation of SV40-con-
taining supernatant from infected CV1 and Vero cultures and
subsequent use of these viral stocks in infection experiments was as
described previously (Stang et al., 1997). Stocks used to generate
SV40 supernatants were a generous gift from Dr. Jurgen Kartenbeck
(Division of Cell Biology, German Cancer Research Center, Heidel-
berg, Germany).
Microinjection
Antibody samples for microinjection were each prepared as previ-
ously described in the cited references. Purified rabbit IgG (Sigma-
Aldrich) solubilized in 10 mM KH2PO4, pH 7.2, and 75 mM KCl
microinjection buffer (Henley et al., 1998) was injected at 10 mg/ml
as a control. Plasmid DNA for microinjection was purified on a
cesium chloride gradient and injected into the nucleus of cells at
50–100 g/ml. Capillary microinjection of antibodies and DNA into
cells was performed using a computer-assisted, automated micro-
injection system (CompiC INJECT, AIS2; Cellbiology Trading, Ham-
burg, Germany) by using microcapillaries pulled from thin-wall
borosilicate glass capillaries (1.2-mm outer diameter; 0.94-mm inner
diameter) (Clark Electromedical Instruments, Pangbourne Reading,
England) by a Flaming/Brown P-97 micropipette puller (Sutter,
Novato, CA). Cells to be injected were plated onto small glass
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coverslips and injected at room temperature (RT) in Hanks’ medium
containing 0.75 mg/ml bicarbonate and 10 mM HEPES, pH 7.4.
Cells were allowed to recover for 0.5–4 h postinjection (or 5 h for
expression of injected cDNA) in penicillin-streptomycin–containing
medium at 37°C before subsequent manipulations.
Immunofluorescence and Electron Microscopy
Experiments requiring immunolabeling with the monoclonal anti-
body to SV40 T-antigen were fixed in 100% methanol for 5 min at
20°C. Microinjection experiments requiring this fixation were of-
ten first fixed with 4% paraformaldehyde (PFA) in phosphate-buff-
ered saline (PBS) at RT for 20 min and subsequently fixed with 100%
methanol as described above. This reduced the washing out of the
injected antibody by methanol fixation. All other experiments were
fixed only with 4% PFA in PBS at RT for 20 min. Processing of cells
for immunofluorescence analysis was as follows. PFA-fixed cells
were permeabilized in 0.1% saponin in PBS for 10 min before
subsequent incubation in 50 mM NH4Cl in PBS for 10 min (to
quench aldehyde groups) and in blocking solution (composed of
0.2% bovine serum albumin and 0.2% fish skin gelatin in PBS) for 20
min at RT. A 30-min incubation in blocking solution containing
primary antibodies was followed by 4  5-min PBS washes before
incubation in blocking solution containing fluorescently tagged sec-
ondary antibodies for 20 min. After further 4  5-min PBS washes,
the cells were rinsed in water and mounted in Mowiol mounting
medium. In experiments requiring nuclear staining, the cells were
incubated in 1 g/ml DAPI in PBS for 2 min just before rinsing and
mounting. Cells fixed with methanol did not require saponin per-
meabilization. Experiments were viewed and photographed with an
Olympus BX60 microscope connected to a Daige charge-couple
device camera image capture system. Immunofluorescence images
were prepared using Adobe Photoshop 5.0 (Adobe Systems, Moun-
tain View, CA). Cells were processed for electron microscopy ac-
cording to Stang et al. (1997).
Quantitation of Viral Infection
Infection efficiencies of 20 or more antibody-injected cells and 40 or
more transfected cells per experiment were quantified. For drug
treatment and temperature-sensitivity experiments, efficiency of in-
fection was quantified from 100 or more cells from each treatment.
RESULTS
Surface-to-ER Traffic of SV40
SV40 has been shown to be internalized by caveolae and
then to reach a subdomain of the ER. The molecular machin-
ery and sorting mechanisms by which the virus reaches the
compartment are presently unknown.
We first examined the nature of the SV40-containing com-
partment by using both plastic sections and immunolabel-
ing. Epon sections of cells incubated with SV40 for 21 h
revealed the virus in reticular, smooth-membraned areas of
the ER connected to ribosome-studded rough ER mem-
branes (Figure 1, A and B). The membrane is closely ap-
posed to the surface of the viral particles, suggesting that the
virus remains bound to the lumenal surface of the mem-
brane. Ultrathin frozen sections of these cells were labeled
with antibodies to the virus together with antibodies to a
cis-Golgi marker, p23, or to a marker of the ER, PDI. The
virus-containing membranes were negative for the cis-
Golgi/intermediate compartment labeled by antibodies to
p23 (our unpublished data) but were labeled by antibodies
to PDI (Figure 1C). Although the majority of the virus par-
ticles was observed in these very prominent enlarged ER
domains, virus particles were occasionally observed in prox-
imity to the Golgi complex, and possibly in Golgi-associated
membranes (our unpublished data), raising the possibility
Figure 1. Electron microscopic localization of SV40 in PDI-positive subdomain of ER. Vero cells were incubated with SV40 for 18 to 21 h
at 37°C before fixation and processing for either epon embedding (A and B) or frozen sectioning (C). (A and B) SV40 accumulates in a domain
of the rough ER. Virus particles (large arrowheads) are in smooth-membraned areas of the rough ER; ribosomes (small arrowheads in B) are
evident on cisternae connected to the SV40-containing structures. (C) Frozen section labeled for SV40 (large gold, large arrowheads) and for
PDI (small gold, small arrowheads) showing colocalization of the virus with the ER marker. N, nucleus. Bars, 200 nm.
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that virus may transiently associate with these compart-
ments during infection.
Brefeldin A Inhibits Entry and Postentry Trafficking
of SV40
The above-described observations prompted us to further
examine the possibility that SV40 passes transiently through
the Golgi compartment in a similar manner to many bacte-
rial toxins, which also follow an endocytic route to the ER.
Because transient intermediates in infection may be difficult
to identify morphologically and the viral infection process is
relatively unsynchronized, we chose to use defined mem-
brane trafficking inhibitors together with assays of infection
to further delineate the trafficking pathway.
We first examined the possible involvement of the Golgi
complex in the SV40 trafficking pathway by using the fungal
metabolite BFA. This drug inhibits guanine nucleotide ex-
change on the small GTPase Arf1 (Jackson and Casanova,
2000), an adapter protein responsible for recruitment of
COPI coats onto endosomal and biosynthetic membranes.
The result is an inhibition of anterograde transport from ER
to Golgi complex (Misumi et al., 1986) and a concomitant
tubulation and fusion of the Golgi with the ER (Lippincott-
Schwartz et al., 1989; Scheel et al., 1997). Consequently, BFA
has been widely used to inhibit both anterograde and retro-
grade transport between the Golgi complex and ER. Vero
cells were pretreated for 3 h with BFA and then incubated
with SV40 plus BFA for 21 h before fixation and immuno-
labeling for the virus-encoded T-antigen (T-ag). As shown in
Figure 2, BFA is a potent inhibitor of SV40 infection. With
concentrations as low as 0.1 g/ml we observed 99% inhi-
bition of infection (Figure 2E). These relatively low doses of
0.1 and 0.5 g/ml BFA were found to be effective in dis-
rupting Golgi morphology within 1 and 3 h of treatment,
respectively (Figure 2, A and B).
To determine the stage of the infectious entry pathway
that was affected by BFA, Vero cells were exposed to a 3-h
pulse treatment of 0.1 g/ml BFA at various time points into
SV40 infection at 37°C. Fixation and immunolabeling for
T-ag after the 21-h infection period revealed a clear inhibi-
tion of SV40 infection when BFA was applied at early stages
of viral infection (Figure 2E). To examine the possibility that
BFA blocks viral entry, we made use of a neutralizing anti-
SV40 antibody, which inactivates surface virus. Addition of
the neutralizing antibody to cells incubated with the virus at
4°C with no warming step to allow internalization caused a
complete block of infection (our unpublished data). Vero
cells cultured in the presence or absence of 0.5 g/ml BFA
for 1 h at 37°C were incubated with SV40 plus or minus BFA
on ice for 1 h and then at 37°C for 2 h to allow infection to
occur. The cells were then incubated in SV40 neutralizing
antibody for 30 min and washed to remove BFA. A further
46 h of infection at 37°C was followed by fixation and
immunofluorescence labeling for T-ag. Quantitation of SV40
infection efficiency revealed a substantially greater sensitiv-
ity of SV40 infection to the neutralizing antibody in BFA-
treated cells compared with untreated cells, indicating a
trapping of the virus at the cell surface by BFA (Figure 2F).
Thus, it was apparent that the first effect of BFA on SV40
infection was the inhibition of initial viral entry. Consistent
with this, treatment with 0.3 g/ml BFA and incubation
with the virus for 21 h showed SV40 immunolabeling only at
the periphery of cells, unlike the pattern observed in un-
treated controls (Figure 2, C and D). Dual immunolabeling
for caveolin-1 and SV40 revealed no significant colocaliza-
tion (our unpublished data). Similar results were obtained in
cells transiently transfected with caveolin-1-YFP with no
colocalization of peripheral SV40 labeling with caveolin-1-
YFP (our unpublished data). Epon sections of these cells
revealed virus particles in tight-fitting, surface-connected
invaginations indistinguishable from those seen in un-
treated cells at early time points. In accordance with the
immunofluorescence data, few virus particles were ob-
served intracellularly (Figure 2G).
To investigate whether BFA also inhibits postsurface traf-
ficking steps, Vero cells were incubated with SV40 for 2 h at
37°C in the absence of BFA to allow viral infection to pro-
ceed past the initial internalization step. Any virus remain-
ing at the cell surface was then inactivated with neutralizing
antibody and the cells incubated in either the presence or
absence of 0.5 g/ml BFA for the remaining 20 h of infec-
tion. Quantitation revealed a strong inhibition of infection in
BFA-treated cells compared with untreated controls, show-
ing inhibition of an internal step in SV40 infection (Figure
2H).
We conclude that the initial entry step of SV40 entry is
BFA sensitive. In addition, SV40 infection involves a second
postentry BFA-sensitive step, possibly involving endosomes
and/or the Golgi complex.
SV40 Entry Is Inhibited at 20°C
Although BFA is best known for its inhibitory effect on
transport between ER and Golgi complex, it has also been
shown to inhibit early endosome-to-Golgi complex traffic
(e.g., of endocytosed Shiga toxin; Mallard et al., 1998). To
determine whether SV40 is internalized to early endosomes,
we made use of the observation that exit from the early
endosome is blocked at 20°C (Griffiths et al., 1988). Vero cells
were infected with SV40 at 20°C for 4 h. Fixation and im-
munolabeling for the virus revealed a striking loss of stain-
ing for the virus (our unpublished data). To confirm this
apparent failure of the virus to be internalized at 20°C, we
again used the SV40 neutralizing antibody assay. Vero cells
were infected with the virus either at 20 or at 37°C for 4 h.
Subsequent exposure of the cells to the neutralizing anti-
body for 30 min was followed by incubation at 37°C for a
further 24 h before fixation and immunolabeling for T-ag.
Quantitation of infection efficiency revealed a much greater
sensitivity of the virus to the neutralizing antibody after a
4-h infection at 20°C than after infection at 37°C (Figure 3).
We conclude that initial entry of SV40 is sensitive to both
BFA and incubation at 20°C.
CT Exit from Early Endosomes Is Inhibited by BFA
and by Incubation at 20°C
We next examined the effects of these treatments on a well-
characterized retrograde transport pathway. CT is efficiently
transported to the ER via the Golgi complex (see INTRO-
DUCTION). We have used either FITC-labeled CT-B (CT-B-
FITC), which is transported to the Golgi, or immunolabeling
for the holotoxin, which is transported to the ER (Lencer,
2001). Vero cells allowed to bind and internalize the FITC-
Retrograde Transport of SV40
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Figure 2. BFA sensitivity of early events in SV40 infection. Treatments of 0.1 g/ml BFA for 3 h (B) were found to disrupt the Golgi complex
of Vero cells (cf. untreated cells in A) as revealed by immunolabeling for the Golgi marker giantin. In Vero cells treated with 0.1 g/ml BFA
for 3 h and subsequently infected with SV40 for 21 h in the continued presence of the drug, a potent inhibition of viral infection was observed
(E; BFA control). Immunolabeling for SV40 (green) and nuclear staining with DAPI (blue) revealed an accumulation of the virus at the
periphery of cells treated with BFA (D), a pattern clearly different from that observed in untreated cells (C). (E) When the 3-h BFA treatment
was applied at various time points after the commencement of infection, a sensitivity to the drug of early but not later events in SV40 infection
was evident. A representative experiment is shown. (F) BFA inhibits SV40 internalization. Vero cells cultured in 0.5 g/ml BFA for 1 h were
allowed to internalize SV40 for 2 h at 37°C in the presence or absence of the drug. Subsequent exposure of the cells to an SV40 neutralizing
antiserum allowed inactivation of all surface-exposed virus before a further 46 h of infection in the absence of the drug. Fixation and
immunolabeling for T-ag revealed a substantially greater sensitivity of virus infection to the neutralizing antiserum in BFA-treated cells
compared with untreated controls. A representative experiment is shown. Infection efficiencies are shown normalized to those of controls not
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labeled B subunit of the toxin at 20°C showed no inhibition
of toxin accumulation in early endosomes (Figure 4, A–C).
Similarly, Vero cells pretreated for 1 h with 0.5 g/ml
BFA also internalized the toxin to early endosomes (Fig-
ure 4, D–F). In cells exposed to BFA for a 21-h period
comparable with that used in SV40 infection experiments,
internalization of CT was still observed, although a
greater intensity of plasma membrane fluorescence, pos-
sibly indicating a decrease in uptake, was detected (our
unpublished data).
Although BFA and a 20°C incubation had little effect on
internalization of CT-B, subsequent transport to the Golgi
was completely inhibited by both treatments. Even after a
1-h incubation at 20 or 37°C in the presence of BFA, the toxin
failed to reach the Golgi (Figure 4, A–F). In cells exposed to
BFA (Figure 4, D–I) the toxin accumulated in sorting endo-
somes and tubulated recycling endosomes identified by co-
localization of cointernalized Texas Red-labeled transferrin
with CT-B-FITC (Figure 4, G–I). We conclude that the sen-
sitivity of SV40 entry to both BFA and incubation at 20°C is
in contrast to other known endocytic pathways, including
that of the putative caveolae marker CT (Lencer et al., 1993;
Nambiar et al., 1993) and suggests that SV40 uses a novel
entry pathway.
Inhibition of SV40 Infection by Microinjected
Antibodies to COP and by Expression of Arf1 and
Sar1 Mutants
The sensitivity of a postsurface SV40 trafficking step to BFA
treatment raised the possibility of Golgi complex involve-
ment in the viral entry pathway. Inhibition of retrograde
traffic between the Golgi complex and ER has been convinc-
ingly demonstrated by microinjection of an antibody to
COP, a component of the coatomer complex of COPI-
coated vesicles. Microinjection of anti-COP (EAGE) (Pep-
perkok et al., 1993) was found to inhibit COPI-mediated
retrograde transport of the KDEL receptor and of ERGIC-53,
both molecules that constitutively cycle between the ER and
Golgi complex (Girod et al., 1999). Retrograde traffic of en-
docytosed CT-A subunit has also been found to be inhibited
by anti-COP injection (Majoul et al., 1998; Girod et al., 1999).
Vero cells were microinjected with anti-COP antibodies.
Three to four hours later the cells were infected with SV40
for 21 h before fixation and immunolabeling for the micro-
injected antibody and T-ag. The microinjected antibodies
showed cytosolic labeling and strong Golgi staining (Figure
5A). Quantitation of infection efficiency revealed a strong
inhibition of viral infection in microinjected cells, compared
with surrounding uninjected cells (Figure 5B), showing that
the anti-COP antibody is a potent inhibitor of SV40 infec-
tion.
As a second independent method to inhibit COPI-medi-
ated transport we used overexpression of a GTPase-deficient
Arf1 mutant (Q71L). This mutant has previously been
shown to inhibit COPI-dependent transport in the early
secretory pathway (Dascher and Balch, 1994) and also to
inhibit sorting and concentration of cargo molecules into
COPI-coated vesicles in vitro (Lanoix et al., 1999). Vero cells
were microinjected with either a mixture of Arf1(Q71L) and
GFP expression plasmids or the GFP plasmid alone (as a
control). After 5 h to allow expression of proteins the cells
were incubated with SV40. Expression of Arf1(Q71L) in
GFP-expressing cells injected with both plasmids was veri-
fied by immunolabeling the cells for COP. A clear disrup-
tion or complete disappearance of the Golgi COP labeling
pattern in cells showing high levels of GFP expression was
observed in cells injected with both plasmids but not in cells
injected only with the GFP construct (Figure 6, A–D). Quan-
titation of infection efficiency revealed a potent inhibition of
SV40 infection in Arf1(Q71L)-expressing cells compared
with neighboring nonexpressing cells. No such inhibition
was observed in cells expressing GFP alone (Figure 6E).
In addition to their effects on COPI-mediated retro-
grade transport between the Golgi and ER, the dominant
negative Arf1 mutant and microinjected COP antibody
could also be affecting events early in endocytosis because
Arf1 and COP proteins have been implicated in endoso-
mal trafficking (Aniento et al., 1996; Daro et al., 1997; Gu et
al., 1997; Gu and Gruenberg, 2000; Jackson and Casanova,
2000). To determine whether disruption of ER/Golgi
transport could be responsible for inhibiting viral infec-
tion, we examined the effect of a selective inhibitor of
ER/Golgi transport on SV40 infection by expression of the
Figure 2 (cont). exposed to the neutralizing antiserum. (G) Epon
sections of Vero cells cultured in 0.3 g/ml BFA for 3 h and then
infected with SV40 for 21 h in the presence of the drug. Thin sections
revealed an accumulation of virus particles at the cell surface as
shown at low magnification in the inset. The virus accumulates in
apparently normal caveolae-like invaginations (arrowheads).
Empty caveolae are also apparent (arrows). (H) BFA inhibits intra-
cellular trafficking of SV40. Vero cells were infected with SV40 for
2 h at 37°C before exposure to the neutralizing antiserum. Subse-
quent culture with or without 0.5 g/ml BFA for the remaining 20 h
of infection was followed by fixation and immunolabeling for T-ag.
Cell counts revealed a strong inhibition of infection in BFA-treated cells
compared with untreated controls. Infection efficiencies are shown
normalized to those of untreated controls. A representative experiment
is shown. Bars, 20 m (A–D) and 100 nm (G).
Figure 3. SV40 internalization is inhibited at 20°C. Vero cells were
infected with SV40 for 4 h at either 20 or 37°C before neutralizing
surface-exposed virus with SV40 neutralizing antiserum. After sub-
sequent incubation at 37°C for a remaining 24 h, the cells were fixed
and immunolabeled for T-ag. Quantitation of infection efficiency
revealed a much greater sensitivity of the virus to the neutralizing
antibody after infection at 20°C than after infection at 37°C. Infection
efficiencies are shown normalized to controls not exposed to the
neutralizing antiserum. A representative experiment is shown.
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GTP-restricted mutant of Sar1, Sar1(H79G) (Aridor et al.,
1995). We observed that cells coinjected with expression
plasmids for GFP and Sar1(H79G) showed significant in-
hibition of SV40 infection (Figure 6F). Use of a tempera-
ture sensitive form of vesicular stomatitis virus glycopro-
tein (ts-045-G) confirmed that Sar1(H79G) and also
Arf1(Q71L) were potently inhibiting anterograde trans-
port in this system (Figure 7). These results show a direct
Figure 4. Early endosome-to-Golgi transport of CT-B is inhibited at 20°C and by BFA. Incubation of Vero cells in 0.5 g/ml CT-B-FITC for
1 h at 20°C resulted in accumulation of the toxin in EEA1-positive early endosomes (arrows) and a failure of the toxin to reach the Golgi
complex (A–C). Similarly, pretreatment with 0.5 g/ml BFA for 2 h before subsequent internalization of CT-B-FITC in the continued presence
of BFA resulted in toxin delivery to EEA1-positive early endosomes (arrows) without subsequent arrival at the Golgi complex even after 1 h
at 37°C (D–F). In BFA-treated cells, CT-B-FITC was also observed in a tubulated compartment identified as the recycling endosome by
colocalization with cointernalized transferrin-Texas Red (G and I). Bars, 10 m.
Figure 5. Inhibition of SV40 infection by microin-
jection of a COP antibody. Vero cells were micro-
injected with the COP antibody, anti-EAGE, and
subjected to SV40 infection. Fixation and dual im-
munolabeling for the viral nuclear antigen T-ag
(red) and the microinjected antibody (green) al-
lowed detection of infected and injected cells, re-
spectively (A). Cell counts revealed a dramatic inhi-
bition of SV40 infection by the COP antibody (B).
The mean and SEM of three independent experi-
ments are shown. Bar, 20 m.
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or indirect role for Arf1, Sar1, and COP-dependent traf-
ficking steps in SV40 infection.
Inhibition of CT Transport to Golgi by Arf1(Q71L)
and Sar1(H79G)
To further compare the CT and SV40 trafficking pathways,
we examined the effect of the above-mentioned inhibitors on
trafficking of CT-B to the Golgi complex or of CT holotoxin
to the ER. Cells microinjected with plasmids encoding
Arf1(Q71L) and Sar1(H79G) were incubated for 5 h and then
allowed to bind and internalize CT-B-FITC for 40 min. A
clear inhibition of toxin arrival at the Golgi was observed.
The toxin was, however, internalized to early endosomes,
although an obvious increase in intensity of cell-surface
signal indicated a slight inhibition of entry (Figure 8). A
similar inhibition of CT internalization was elicited by mi-
croinjection of the anti-COP antibody (EAGE) (our unpub-
lished data).
We then examined trafficking of CT holotoxin to the ER.
Untreated cells showed that CT reached the ER in 2 h as
judged by immunofluorescence (Figure 9). Vero cells were
injected with the above-mentioned constructs and protein
expression was prevented by incubation with cyclohexi-
mide for 4 h. The cells were then allowed to bind and
internalize CT holotoxin at 20°C for 1 h in the absence of
cycloheximide. After subsequent incubation at 37°C for a
further 2 h, the cells were fixed and immunolabeled for
CT. This protocol allowed initial internalization of CT to
endosomes at 20°C in the absence of mutant protein, but
subsequent transport to the Golgi and ER at 37°C oc-
curred in the presence of newly synthesized mutant pro-
Figure 6. Inhibition of SV40 infection
by Arf1(Q71L) and Sar1(H79G). Vero
cells were injected with either a mix-
ture of Arf1(Q71L) and GFP expres-
sion plasmids (A) or the GFP plasmid
alone (C) and incubated for 5 h to al-
low protein expression to occur. Im-
munolabeling for COP (B and D) re-
vealed an obvious disruption or
complete absence of the Golgi COP
labeling pattern in cells expressing
GFP and Arf1(Q71L) (A and B) but not
in cells expressing only GFP (C and D).
Subjection of these cells to SV40 infec-
tion and quantitation of infection effi-
ciency revealed a potent inhibition in
Arf1(Q71L)-transfected cells compared
with cells expressing GFP alone (E). A
significant inhibition of SV40 infection
was also elicited by a GTPase-deficient
Sar1 mutant in a similar experiment
(F). The graphs show the mean and
SEM of three independent experi-
ments. Infection efficiencies of trans-
fected cells have been normalized to
those of surrounding untransfected
cells. Bars, 40 m.
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teins. As shown in Figure 9, the mutant proteins caused
inhibition of transport to the ER with toxin accumulating
in early endosomes (identified by colocalization with
EEA1; our unpublished data) or perinuclear putative
Golgi elements.
The inhibition of CT transport out of endosomes and to
the Golgi by Arf1(Q71L) is in full accord with the previously
described effect of BFA and could be explained by an Arf1/
COPI-mediated transport step between endosomes and the
Golgi complex. However, the similar inhibition by
Sar1(H79G) can only be due to either disruption of the Golgi
or a reliance of this endocytic pathway on a functional
exocytic pathway.
Inhibition of SV40 Infection by Cbz-gly-phe-NH2
To further compare SV40 infectious trafficking with the traf-
ficking of CT to the ER and then cytosol, we investigated the
effect of a recently described inhibitor of CT toxicity. The
dipeptide benzyloxycarbonyl Cbz-gly-phe-NH2 causes a
potent block in the late stages of toxin action and has no
effect on the initial toxin entry step (De Wolf, 2000). This
agent thus provides an important tool for comparing late
stages in SV40 trafficking with those of CT.
Vero cells were preincubated for 1 h with 2 mM Cbz-gly-
phe-NH2 or an inactive anolog, Cbz-gly-gly-NH2. The cells
were then incubated for 21 h with SV40 in the continued
presence of the same drug. Quantitation of T-ag expression
efficiency revealed a potent inhibition of infection by Cbz-
gly-phe-NH2 (Figure 10A). In contrast, the inactive analog
Cbz-gly-gly-NH2 had no effect at the same concentration
(Figure 10A). Infection was similarly inhibited in cells al-
lowed to internalize the virus for 4 h before inactivation of
surface-exposed SV40 (using the neutralizing antibody) and
simultaneous exposure to the inhibitory dipeptide. This con-
firms an inhibition of the virus postentry (Figure 10D).
To assess whether the drug is specific for a retrograde
trafficking pathway such as that followed by SV40 or CT, we
examined its effects on infection by an enveloped virus, SFV.
This virus enters cells by clathrin-mediated endocytosis and
requires delivery to acidic endosomes for translocation to
the cytosol and productive infection (Marsh et al., 1984).
When Vero cells were exposed to recombinant SFV in the
presence of the drug, no inhibitory effects on infection and
expression of the SFV-encoded protein, caveolin-3 [SFV(cav-
3)], were observed (Figure 10B).
As shown for the inhibition of CT toxicity, the effect of
Cbz-gly-phe-NH2 on SV40 infection was found to be
quickly reversible. Cells pretreated for 1 h before washing
out the drug and infection with SV40 showed no inhibi-
tion of infection compared with untreated controls (our
unpublished data). This suggests no lasting effects of the
1-h pretreatment. Furthermore, as observed for CT inter-
nalization, the block in SV40 infection appeared to be in
late steps of the infectious pathway. A 21-h SV40 infection
in the presence of the drug was followed by various
periods of incubation in the absence of the drug before
fixation and immunolabeling for T-ag. The percentage
infection of treated cells stayed very low for the first 3 h
after washing out the drug but began to recover after 6 h
and reached control levels after 9 h (Figure 10C). This time
period is shorter than that required for infection if virus is
added to the outside of the cells and shows that the virus
accumulates at a late stage in the infectious entry path-
way. In keeping with this, electron microscopy of plastic
sections revealed no detectable difference in the number
of viral particles reaching ER cisternae in inhibitor- and
control-treated cells (our unpublished data).
Finally, we examined CT trafficking in Cbz-gly-phe-NH2–
treated cells. No inhibition of CT-B-FITC arrival to the Golgi
was detected in inhibitor-treated cells, suggesting that only late
events in the toxic entry pathway are affected (Figure 11).
In conclusion, we have identified a potent new reversible
inhibitor of SV40 infection that acts at a late stage in the
infectious entry process. This makes Cbz-gly-phe-NH2 an
invaluable tool for detailed characterization of these traffick-
ing pathways.
Figure 7. Exocytic transport of ts-045-G is inhibited by Sar1(H79G) and Arf1(Q71L). Vero cells were injected with GFP-tagged ts-045-G
expression plasmid alone (A), or with a mixture of ts-045-G and either Sar1(H79G) (B) or Arf1(Q71L) (C) expression plasmids. Subsequent
incubation at the restrictive temperature (39.5°C) for 3 h allowed expression of the mutant proteins and accumulation of ts-045-G in the ER
(our unpublished data). A further 3-h incubation at the permissive temperature (31°C) resulted in delivery of ts-045-G to the plasma
membrane in cells expressing this mutant alone (A). However, in cells expressing either Sar1(H79G) (B) or Arf1(Q71L) (C), ts-045-G remained
trapped in the ER and in perinuclear aggregates and was never seen to reach the plasma membrane. Bar, 20 m.
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DISCUSSION
The present study provides new insights into the pathway by
which a simple nonenveloped virus, SV40, passes from the cell
surface to its site of replication, the nucleus. This pathway
involves transport from cell surface caveolae to a subdomain of
the rough ER. We have examined this pathway morphologi-
cally and then proceeded to use specific inhibitors to disrupt
the infectious entry pathway. We now show that the initial step
in virus entry displays unique characteristics, being blocked by
BFA and by incubation of cells at 20°C. We have also shown
that the virus uses a pathway reliant on Arf1/COPI and Sar1
function to reach the ER. Finally, we have identified a novel
inhibitor of viral infection, the dipeptide Cbz-gly-phe-NH2,
known to block CT toxicity. These studies give fundamental
new insights into the molecular mechanisms involved in this
novel virus entry pathway.
Molecular Characterization of SV40 Entry
SV40 infection proceeds via binding of the virus to MHC
class I molecules on the cell surface (Breau et al., 1992) and
Figure 8. CT transport to the Golgi
complex is inhibited by Arf1(Q71L)
and Sar1(H79G). Vero cells were in-
jected with a mixture of GFP and ei-
ther Arf1(Q71L) (A–D) or Sar1(H79G)
(E–H) expression plasmids. After a 5-h
period of protein expression, the cells
were allowed to bind either CT-B-FITC
or unlabeled holotoxin and internalize
for 40 min at 37°C. Injected cells (iden-
tified by GFP expression shown in A,
C, E, and G) displayed internalization
of the toxin to early endosomes but not
to the Golgi (outlined cells in B, D, F,
and H). An apparent accumulation of
toxin at the cell surface of injected cells
was also often noted and may reflect a
slight reduction in initial internaliza-
tion. Bars, 20 m.
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then association with caveolae (Anderson et al., 1996; Stang
et al., 1997; Chen and Norkin, 1999; Norkin, 1999; Parton and
Lindsay, 1999; Pelkmans et al., 2001). The virus is then in-
ternalized but it is currently unknown whether the virus
promotes internalization or follows the constitutive internal-
ization of caveolae, still a contentious issue. We now show
that the internalization step is blocked by BFA and by incu-
bation at 20°C. This suggests a pathway distinct from other
well-characterized internalization pathways and in particu-
lar, the constitutive entry of CT, a putative caveolar marker.
Although the intracellular effects of BFA are well character-
ized, a role for BFA-sensitive Arf proteins in endocytic path-
ways at the plasma membrane has not been convincingly
demonstrated. Endocytosis of CT, transferrin, and ricin have
all been shown to be BFA independent (Lencer et al., 1993;
Nambiar et al., 1993; Schonhorn and Wessling-Resnick, 1994;
Uhlin-Hansen and Yanagishita, 1995). Similarly, incubation
at 20°C does not inhibit CT entry and has commonly been
used to accumulate ligands in early endosomes due to a
block in traffic out of this compartment but not in initial
internalization (Lencer et al., 1992; Mallard et al., 1998; Pun-
nonen et al., 1998; Ren et al., 1998). Interestingly, a recent
study of trafficking pathways used by various glycosyl
phosphatidylinositol (GPI)-anchored proteins described a
novel endocytic pathway displaying a similar sensitivity to
incubation at 20°C as that of SV40 entry (Nichols et al., 2001).
Such a pathway was shown to convey the raft-associated
proteins, GPI-anchored GFP, and an endogenous GPI-an-
chored protein, CD59, from the plasma membrane to a non-
classical endosomal compartment and finally to the Golgi
complex (Nichols et al., 2001). Another recent morphological
study of the SV40 infectious pathway (Pelkmans et al., 2001)
demonstrated internalization of the virus to a similarly non-
classical endosomal compartment termed by the authors, the
“caveosome.” Common to the caveosome and the GPI-an-
chored protein-containing endosomal compartment is the
absence of classical early endosomal markers such as EEA1
and internalized transferrin. In addition, Pelkmans et al.
(2001) were able to demonstrate the lumenal pH of caveo-
somes to be neutral and also showed caveolin-1 to be a
marker for this compartment. The possibility that inhibition
of SV40 entry and GPI-anchored protein endocytosis at 20°C
reflects an indirect effect of a block in plasma membrane
delivery of key molecules trafficking through the secretory
pathway rather than a direct effect on internalization still
exists. Nevertheless, these pathways display key differences
to known endocytic pathways and future studies will be
aimed at dissecting the novel internalization mechanism.
Figure 9. CT transport to the ER is inhibited by Arf1(Q71L) and Sar1(H79G). Vero cells were injected with a mixture of GFP and either
Arf1(Q71L) (A and B) or Sar1(H79G) (C–F) expression plasmids and incubated in 10 g/ml cycloheximide for 4 h. The cells were then allowed
to bind and internalize CT holotoxin in the absence of cycloheximide at 20°C for 1 h and subsequently at 37°C for a further 2 h. Although
the toxin (B, D, and F) clearly reached the ER in uninjected cells (outlined in A, C, and E), cells expressing the Arf1 or Sar1 mutants (identified
by GFP expression shown in A, C, and E) displayed a conspicuous lack of toxin in the ER. Instead, an accumulation of the toxin in endosomes
and sometimes the Golgi was observed in injected cells. Bars, 10 m.
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Involvement of Arf1, COP, and Sar1 in
SV40 Trafficking
The most striking finding of this study is that SV40 passes
from the cell surface to its site of replication via a BFA-
sensitive pathway dependent on Arf1/COPI function and
Sar1 function. In parallel experiments, we have shown that
intracellular trafficking of cholera toxin is also sensitive to
BFA, disruption of Arf1/COPI function, and disruption of
Sar1 function. The block in Golgi-to-ER transport of the toxin
by microinjection of anti-COP (EAGE) has been previously
described (Majoul et al., 1998). However, we herein demon-
strate the inhibition of early endosome-to-Golgi transport of
the toxin by BFA, COP antibodies, Arf1(Q71L), and
Sar1(H79G). A similar inhibition of the transport of Shiga
toxin (a related toxin) from early endosomes to the Golgi by
BFA has been described previously (Mallard et al., 1998), but
the discovery of Sar1 involvement in such a pathway is
unprecedented and sheds new light on the possible mecha-
nism of inhibition. One interpretation is that Arf1 and COPI
coats assembling on early endosomes mediate toxin trans-
port to the trans-Golgi network (because it is well known
that Arf1 mediates assembly of COP proteins on early en-
dosomal membranes as well as Golgi membranes; Aniento et
al., 1996; Daro et al., 1997; Gu et al., 1997; Gu and Gruenberg,
2000; Jackson and Casanova, 2000). However, this does not
explain Sar1(H79G)-mediated inhibition of the same step
because the Sar1 GTPase is known to function only in ER-
to-Golgi traffic (Aridor et al., 1995). Alternatively, because
Arf1/COPI function and Sar1 function are both required for
anterograde transport from the ER to Golgi (Aridor et al.,
1995; Rowe et al., 1996; Pepperkok et al., 1998), it is feasible
that early endosome-to-Golgi traffic is indirectly dependent
on critical regulatory molecules delivered by a functional
exocytic pathway. Such a dependence of endocytic path-
ways on a functional exocytic pathway could also explain
accumulation of CT in early endosomes at 20°C, and inhibi-
tion of SV40 at the plasma membrane by BFA and at 20°C
because exocytic traffic from the trans-Golgi network is in-
hibited at 20°C (Pepperkok et al., 1993). Whether this reflects
a need for newly synthesized caveolin-1 at the cell surface
for virus internalization remains to be determined.
It is important to note that subsequent to the initial entry
of the virus, an intracellular step was also found to be
inhibited by BFA. The affected trafficking step in the infec-
tious pathway still remains unresolved; electron microscopic
analysis of plastic sections has proven difficult due to dra-
matic alteration of the morphology of intracellular compart-
ments by the inhibitory agents used (our unpublished data).
It is also possible that BFA, COP antibodies, Arf1(Q71L),
and Sar1(H79G) are all inhibiting retrograde transport of the
virus from Golgi to ER. This is however inconsistent with
the findings of the Pelkmans et al. (2001) study, which
showed an absence of colocalization of Texas Red-labeled
SV40 with Golgi markers at any time during infection. In-
stead, live fluorescence microscopy revealed the cointernal-
ization of the virus with GFP-tagged caveolin-1 to the caveo-
some compartment from where the virus was sorted away
from caveolin-1 and transported along microtubule tracks to
a perinuclear compartment identified as the ER by colocal-
ization with ER markers. Our studies provide additional
tools for future characterization of this as yet poorly under-
stood infectious pathway and the molecular machinery in-
volved.
Inhibition of SV40 Infection by Cbz-gly-phe-NH2
To further compare the properties of the SV40 and CT entry
pathways, we used the dipeptide benzyloxycarbonyl Cbz-
gly-phe-NH2, which has recently been demonstrated to in-
hibit late stages in CT toxicity (De Wolf, 2000). We now show
that this drug, but not an inactive related dipeptide, is a
potent and reversible inhibitor of SV40 infection. Initial char-
acterization of the inhibition of SV40 infection showed that
the drug is affecting a late stage of viral infection. Similarly,
we found no apparent inhibition by the drug of early steps
in uptake and delivery of CT-B-FITC to the Golgi compart-
ment, confirming the observations of De Wolf. Infection by
SFV, which enters cells via clathrin-coated pits and passes to
acidic endosomal compartments before translocation to the
Figure 10. Cbz-gly-phe-NH2
inhibits SV40 infection but not
SFV infection. (A) Vero cells were
pretreated for 1 h with 2 mM
Cbz-gly-phe-NH2 or its inactive
analog Cbz-Gly-Gly-NH2, or
were untreated. Subsequent in-
fection with SV40 in the contin-
ued presence or absence of the
dipeptides was followed by fixa-
tion and immunolabeling for
T-ag. Quantitation of infection efficiency revealed a consistent inhibition of SV40 infection by the Cbz-gly-phe-NH2 but not its inactive analog.
The mean and SEM of three independent experiments are shown. (B) Vero cells pretreated with 2 mM Cbz-gly-phe-NH2 for 1 h or left
untreated were subjected to SFV infection in the continued presence or absence of the drug. Quantitation of infection efficiency revealed no
inhibition of SFV infection in treated cells. The mean and SEM of three independent experiments are shown. (C) Vero cells were pretreated
for 1 h with 2 mM Cbz-gly-phe-NH2 before a 21-h infection with SV40 in the continued presence of the drug. The cells were then washed
and incubated for various periods in the absence of the drug. Although infection efficiency remained low for the first 3 h after washing out
the drug, a recovery of T-ag expression began to be seen after 6 h and was complete after 9 h in the absence of the drug. Infection efficiencies
are shown normalized to those of untreated controls. A representative experiment is shown. (D) Vero cells were infected with SV40 for 4 h
before inactivation of surface-exposed virus by exposure to SV40 neutralizing antiserum. The cells were then incubated in medium containing
2 mM Cbz-gly-phe-NH2 or its inactive analog for a further 20 h of infection. Quantitation of T-ag expression revealed a potent inhibition of
infection by the dipeptide inhibitor. The mean and SEM of three independent experiments are shown.
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cytosol, was completely unaffected by the drug, emphasiz-
ing the specificity of the inhibition for the SV40 and CT
pathways. Also, production of the membrane protein SFV-
(cav-3) upon infection indicates that inhibition of protein
translation was not occurring in these experiments, although
such an effect of the drug has been described by others
(Strous et al., 1988; Brostrom et al., 1991; Prostko et al., 1992).
Similarly, expression of a cytosolic protein, GFP, under the
SV40 promoter was found to be equally competent in treated
and untreated cells (our unpublished data). Thus, the inhi-
bition of T-ag expression after SV40 infection of treated cells
cannot be attributed to an inhibition of protein translation.
How does this dipeptide affect SV40 infection and is it acting
in a similar manner to block both CT action and SV40
infection? Cbz-gly-phe-NH2 is a metalloprotease inhibitor
but the drug is known to cause depletion of intracellular
stores of calcium and lowers cytosolic calcium (Brostrom et
al., 1991). This effect on calcium stores is thought to underlie
its inhibition of membrane trafficking events between the ER
and Golgi complex, and the Golgi complex and plasma
membrane (Strous et al., 1988; Gravotta et al., 1990;
Kuznetsov et al., 1992; Ivessa et al., 1995) and increasing
extracellular levels of calcium has been found to rescue this
inhibition (Kuznetsov et al., 1992). However, we have found
that the inhibition of SV40 infection still occurs in the pres-
ence of elevated extracellular calcium levels (our unpub-
lished data). Identical results were obtained for the inhibi-
tion of CT toxicity by Cbz-gly-phe-NH2 (De Wolf, 2000).
This is suggestive of a common mechanism of inhibition of
these two processes that differs from previously described
effects of the drug. It has also been suggested that Cbz-gly-
phe-NH2 may affect channels involved in CT transport to
the cytosol (De Wolf, 2000). This hypothesis can now be
tested and may render this drug a valuable tool for dissect-
ing the enigmatic late steps in SV40 translocation.
In summary, we have identified hitherto unexpected
COP-dependent trafficking steps involved in SV40 infection.
The cellular machinery and the sorting mechanisms direct-
ing SV40 along this novel route now await dissection. The
tools described herein should prove powerful in further
efforts to dissect, and possibly exploit, this novel viral traf-
ficking pathway.
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